Takeda Pharmaceutical Co Ltd
XHAM:TKD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Takeda Pharmaceutical Co Ltd (TKD) under the Base Case is 31.08 EUR per share.
Compared with the current market price of 37.34 EUR, the stock appears
Overvalued by 17% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Takeda Pharmaceutical Does
Takeda Pharmaceutical is a global drug company that researches, develops, manufactures, and sells prescription medicines. Its main products focus on areas like gastrointestinal disease, rare diseases, plasma-derived therapies, oncology, and neuroscience. It sells these medicines to hospitals, doctors, pharmacies, and health systems around the world through its own sales force and distribution partners.
- Headquarters
- Japan JP
- Employees
- 47 455
- IPO date
- May 16, 1949
Takeda Pharmaceutical has no economic moat
Patent protection shields individual Takeda medicines, but it does not keep competitors out across the whole company for the long term. Generic copies can take sales after protection ends, while rival treatments compete even with protected medicines.
Read the full moat analysis
Revenue & Expenses Breakdown
Takeda Pharmaceutical Co Ltd
Earnings Waterfall
Takeda Pharmaceutical Co Ltd
What is the Intrinsic Value of one TKD stock?
The intrinsic value for Takeda Pharmaceutical Co Ltd (TKD) under the Base Case is 31.08 EUR.
Is TKD stock undervalued or overvalued?
Compared with the current market price of 37.34 EUR, the stock appears Overvalued by 17% .
